Blood flow is a major regulator of hemostasis and arterial thrombosis. The current view is that low and intermediate flows occur in intact healthy vessels, whereas high shear levels (>2000 s−1) are reached in stenosed arteries, notably during thrombosis. To date, the shear rates occurring at the edge of a lesion in an otherwise healthy vessel are nevertheless unknown. The aim of this work was to measure the shear rates prevailing in wounds in a context relevant to hemostasis. Three models of vessel puncture and transection were developed and characterized for a study that was implemented in mice and humans. Doppler probe measurements supplemented by a computational model revealed that shear rates at the edge of a wound reached high values, with medians of 22 000 s−1, 25 000 s−1, and 7000 s−1 after puncture of the murine carotid artery, aorta, or saphenous vein, respectively. Similar shear levels were observed after transection of the mouse spermatic artery. These results were confirmed in a human venous puncture model, where shear rates in a catheter implanted in the cubital vein reached 2000 to 27 000 s−1. In all models, the high shear conditions were accompanied by elevated levels of elongational flow exceeding 1000 s−1. In the puncture model, the shear rates decreased steeply with increasing injury size. This phenomenon could be explained by the low hydrodynamic resistance of the injuries as compared with that of the downstream vessel network. These findings show that high shear rates (>3000 s−1) are relevant to hemostasis and not exclusive to arterial thrombosis.
Cardiovascular diseases caused by blood coagulation system disorders are one of the leading causes of morbidity and mortality in the world. Research shows that blood clotting factors are involved in these thrombotic processes. Among them, factor Xa occupies a key position in the blood coagulation cascade. Another coagulation factor, XIa, is also a promising target because its inhibition can suppress thrombosis with a limited contribution to normal hemostasis. In this regard, the development of dual inhibitors as new generation anticoagulants is an urgent problem. Here we report the synthesis and evaluation of novel potential dual inhibitors of coagulation factors Xa and XIa. Based on the principles of molecular design, we selected a series of compounds that combine in their structure fragments of pyrrolo[3,2,1-ij]quinolin-2-one and thiazole, connected through a hydrazine linker. The production of new hybrid molecules was carried out using a two-stage method. The reaction of 5,6-dihydropyrrolo[3,2,1-ij]quinoline-1,2-diones with thiosemicarbazide gave the corresponding hydrazinocarbothioamides. The reaction of the latter with DMAD led to the target methyl 2-(4-oxo-2-(2-(2-oxo-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1(2H)-ylidene)hydrazineyl)thiazol-5(4H)-ylidene)acetates in high yields. In vitro testing of the synthesized molecules revealed that ten of them showed high inhibition values for both the coagulation factors Xa and XIa, and the IC50 value for some compounds was also assessed. The resulting structures were also tested for their ability to inhibit thrombin.
To develop efficient and structurally novel anticoagulants, a library of new hybrid molecules—(Z)-1-(2-(4-arylthiazol-2-yl)hydrazineylidene)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-ones—was designed and synthesized through a two-step approach. The reaction of pyrrolo[3,2,1-ij]quinoline-1,2-diones with thiosemicarbazide produced thiosemicarbazones, which were subsequently reacted with α-bromoacetophenones. The structure of the resulting compounds was determined by HPLC-HRMS-ESI analysis, 1H NMR spectroscopy, and 13C NMR spectroscopy. X-ray diffraction analysis unambiguously confirmed the structure of the resulting substances. The synthesized compounds were tested for their anticoagulant activity in vitro. Among the tested derivatives, two substances have a dual effect and exhibit 98–100% inhibitory ability against blood coagulation factors Xa and XIa at 30 μM. IC50 values were also evaluated for these compounds. The results obtained show the high potential of the synthesized derivatives in the development of new multitarget anticoagulant drugs. The docking studies confirmed the experimental results.
Metastatic dissemination remains the leading cause of mortality in malignant tumors, yet the processes of intravasation and extravasation of circulating tumor cells (CTC) are still not fully understood. Existing microfluidic experimental systems possess a number of limitations that prevent them from reproducing physiological conditions. Here we propose a perfused biotechnological system designed to model key stages of the metastatic cascade under controlled flow. The construction includes a parallel-plate flow chamber formed between polyethylene terephthalate plates and surrounded by a collagen gel containing life human dermal fibroblasts. Matrix parameters were optimized, and it was established that a collagen concentration of 20 mg/mL provides mechanical stability, sustained cell viability, and gel robustness under flow. The system also supports the formation of a two-component cellular microenvironment: fibroblasts embedded within the matrix and endothelial cells forming a layer on its surface. An integrated open reservoir effectively eliminated air bubbles and stabilized hydrodynamics, representing a major advantage over conventional microfluidic systems. 48 hour long perfusion of full medium with cells demonstrated long-term cell viability and preservation of channel geometry under continuous perfusion. The developed system combines the benefits of 3D hydrogels and dynamic models while overcoming critical limitations of classical microfluidic devices, and it may serve as a reproducible platform for studying mechanisms of metastasis.
14 April 2026 in Pediatric Hematology/Oncology and Immunopathology
Introduction. Local inflammation commonly accompanies wounds, yet its impact on the dynamics of thrombus formation and hemostatic clot architecture remains poorly explored. Aim: to investigate the influence of local inflammation on the dynamics of clot formation and hemostatic clot architecture. Material and methods. In our models, we used 6–12-week-old ICR mice. Local inflammation was induced by a subcutaneous or intraperitoneal injection of hydroxyethyl cellulose gel containing lipopolysaccharide (LPS) (50 µg). Pathological thrombosis was assessed in a FeCl3-induced carotid artery thrombosis model with fluorescence imaging. Hemostatic clots were assessed in a kidney bleeding model followed by histological staining for fibrin/fibrinogen, CD41, and nuclei. Results. In the FeCl3-induced arterial model, there were no significant differences between the control group and the local inflammation group (LPS group) in the time to initial thrombus formation (406 ± 189 s vs 522 ± 338 s; p 0.05), the maximal thrombus height (560 ± 65 µm vs 650 ± 73 µm; p 0.05), and the initial rate of clot growth (1 × 10–4 ± 8 × 10–5 mm2/s vs 4 × 10–4 ± 6 × 10–5 mm2/s; p 0.05). However, the residual thrombus height was higher in the LPS group (250 ± 237 µm vs 595 ± 107 µm; p 0.05). In the kidney bleeding model, the area of CD41 signal (3900 ± 1800 µm2 vs 47 000 ± 44 000 µm2; p 0.05) and the area of signal from fibrinogen (117 000 ± 33 000 µm2 vs 120 000 ± 120 000 µm2; p 0.05) did not differ between the control group and the LPS group, whereas the nuclear signal area was reduced in the LPS group (11 000 ± 9000 µm2 vs 3200 ± 400 µm2; p 0.05). Conclusion. Local LPS-driven inflammation does not accelerate early FeCl3-induced thrombus formation but is associated with increased thrombus persistence. In large tissue wounds, it does not measurably alter the fibrin-platelet component of the hemostatic clot while reducing nucleated cell accumulation.